TY - JOUR
T1 - Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay
AU - Ulndreaj, Antigona
AU - Sohaei, Dorsa
AU - Thebault, Simon
AU - Pons-Belda, Oscar D.
AU - Fernandez-Uriarte, Amaia
AU - Campbell, Christopher
AU - Cheo, David
AU - Stengelin, Martin
AU - Sigal, George
AU - Freedman, Mark S.
AU - Scarisbrick, Isobel A.
AU - Prassas, Ioannis
AU - Diamandis, Eleftherios P.
N1 - Funding Information:
Dr. Ulndreaj is supported by a post-doctoral fellowship from the University of Toronto’s Medicine by Design initiative, which receives funding from the Canada First Research Excellence Fund (CFREF).
Funding Information:
Research funding: The development of the MSD assays was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U24AI118660. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding for the Quanterix assays was provided by the Ottawa Hospital Innovation Grant.
Publisher Copyright:
© 2023 Walter de Gruyter GmbH. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Neurofilament light (NfL) chain is a marker of neuroaxonal damage in various neurological diseases. Here we quantitated NfL levels in the cerebrospinal fluid (CSF) and serum from patients with multiple sclerosis (MS) and controls, using the R-PLEX NfL assay, which employs advanced Meso Scale Discovery® (MSD) electrochemiluminescence (ECL)-based detection technology. NfL was quantitated in samples from 116 individuals from two sites (Ottawa Hospital Research Institute and Mayo Clinic), consisting of patients with MS (n=71) and age-and sex-matched inflammatory neurological controls (n=13) and non-inflammatory controls (n=32). Correlation of NfL levels between CSF and serum was assessed in paired samples in a subset of MS patients and controls (n=61). Additionally, we assessed the correlation between NfL levels obtained with MSD's R-PLEX® and Quanterix's single molecule array (Simoa®) assays in CSF and serum (n=32). Using the R-PLEX, NfL was quantitated in 99% of the samples tested, and showed a broad range in the CSF (82-500,000 ng/L) and serum (8.84-2,014 ng/L). Nf-L levels in both biofluids correlated strongly (r=0.81, p<0.0001). Lastly, Nf-L measured by MSD's R-PLEX and Quanterix's Simoa assays were highly correlated for both biofluids (CSF: r=0.94, p<0.0001; serum: r=0.95, p<0.0001). We show that MSD's R-PLEX NfL assay can reliably quantitate levels of NfL in the CSF and serum from patients with MS and controls, where levels correlate strongly with Simoa.
AB - Neurofilament light (NfL) chain is a marker of neuroaxonal damage in various neurological diseases. Here we quantitated NfL levels in the cerebrospinal fluid (CSF) and serum from patients with multiple sclerosis (MS) and controls, using the R-PLEX NfL assay, which employs advanced Meso Scale Discovery® (MSD) electrochemiluminescence (ECL)-based detection technology. NfL was quantitated in samples from 116 individuals from two sites (Ottawa Hospital Research Institute and Mayo Clinic), consisting of patients with MS (n=71) and age-and sex-matched inflammatory neurological controls (n=13) and non-inflammatory controls (n=32). Correlation of NfL levels between CSF and serum was assessed in paired samples in a subset of MS patients and controls (n=61). Additionally, we assessed the correlation between NfL levels obtained with MSD's R-PLEX® and Quanterix's single molecule array (Simoa®) assays in CSF and serum (n=32). Using the R-PLEX, NfL was quantitated in 99% of the samples tested, and showed a broad range in the CSF (82-500,000 ng/L) and serum (8.84-2,014 ng/L). Nf-L levels in both biofluids correlated strongly (r=0.81, p<0.0001). Lastly, Nf-L measured by MSD's R-PLEX and Quanterix's Simoa assays were highly correlated for both biofluids (CSF: r=0.94, p<0.0001; serum: r=0.95, p<0.0001). We show that MSD's R-PLEX NfL assay can reliably quantitate levels of NfL in the CSF and serum from patients with MS and controls, where levels correlate strongly with Simoa.
KW - cerebrospinal fluid
KW - electrochemiluminescence
KW - multiple sclerosis
KW - neurofilament light
KW - R-PLEX
KW - serum
KW - Simoa
UR - http://www.scopus.com/inward/record.url?scp=85148741404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148741404&partnerID=8YFLogxK
U2 - 10.1515/dx-2022-0125
DO - 10.1515/dx-2022-0125
M3 - Article
C2 - 36788117
AN - SCOPUS:85148741404
SN - 2194-8011
JO - Diagnosis
JF - Diagnosis
ER -